1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. GOUT THERAPEUTICS MARKET BY DRUG CLASS
5.1. Introduction
5.2. NSAIDs
5.3. Corticosteroids
5.4. Colchicine
5.5. Urate-Lowering Agents
5.6. Others
6. GOUT THERAPEUTICS MARKET BY DISEASE CONDITION
6.1. Introduction
6.2. Acute Gout
6.3. Chronic Gout
7. GOUT THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Online Pharmacy
8. GOUT THERAPEUTICS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Takeda Pharmaceutical Company Ltd.
10.2. Novartis AG
10.3. AstraZeneca plc
10.4. Horizon Therapeutics plc
10.5. Merck & Co. Inc.
10.6. Teijin Pharma Ltd.
10.7. GlaxoSmithKline, Plc.
10.8. Arthrosi
10.9. Mayo Clinic
10.10. Johns Hopkins Arthritis Center
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES